EPFL Ventures

EPFL Ventures operates as the venture and innovation arm of the Ecole Polytechnique Federale de Lausanne, channeling Swiss engineering and medtech research into the early-stage venture market through a combination of grants, programs, and modest investment checks. The healthcare focus concentrates on medical devices, medtech, and AI/ML applications in clinical settings, reflecting EPFL’s particular research strengths in engineering, robotics, and computational sciences.

The thesis is anchored in the conviction that EPFL produces some of the strongest engineering and medtech research in Europe and that systematic structural support is required to translate that research into commercially viable companies. EPFL Ventures provides the program-level scaffolding, including grants, mentorship, and modest pre-seed capital, that allows research-stage founders to develop their technologies to the point where traditional venture capital becomes appropriate. Healthcare investments under this model tend to be technically deep, often involving medical devices, robotics, surgical technology, or AI-driven imaging and diagnostics.

The firm writes checks generally below $250k at the pre-seed and seed stages, which is appropriate for the academic spinout context. The capital is typically combined with grants and program support rather than functioning as a standalone seed round. Geographically, the focus is Switzerland with strong density in the EPFL ecosystem, though companies with EPFL-affiliated founders operating internationally remain in scope. The investor-program model means founders engage with the broader ecosystem before any capital decision is made, which gives both sides time to evaluate fit and gives the company time to mature toward a fully institutional seed round.

The team operates within the broader EPFL institutional context, which provides access to research labs, technical advisory benches, and the alumni network across Europe and globally. For medtech founders specifically, the institutional access often provides more value than the initial check, since EPFL’s engineering and biomedical research infrastructure can support the kind of technical validation that medical device companies require.

In working with companies, EPFL Ventures is most useful for technical advisory, research collaboration, regulatory pathway navigation in the Swiss context, and bridging founders into the broader Swiss and European venture and corporate ecosystem. The firm has connections into seed and Series A leads in Lausanne, Geneva, Zurich, Paris, Berlin, London, and the US that can lead subsequent rounds when companies are ready. For healthcare founders, the fit is strongest for those with research-driven medtech or healthcare AI companies emerging from the EPFL ecosystem, particularly where the technology requires deep engineering validation. The fit is weaker for purely software-driven digital health companies without a meaningful engineering or medtech research dimension. Founders considering EPFL Ventures should plan to engage with the institutional ecosystem, leverage the technical network, and treat the program and modest capital as part of a longer commercialization arc rather than as a final financing.